StonvexLoading…
StonvexStonvexStonvexCore line items from LAB's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $85.33M | $91.01M | $106.34M | $97.95M |
Operating Income | $-110.25M | $-127.48M | $-76.60M | $-116.20M |
Net Income | $-74.90M | $-138.88M | $-74.66M | $-190.10M |
EPS (Diluted) | $-0.20 | $-0.52 | $-0.94 | $-2.43 |
Total Assets | $567.75M | $612.35M | $323.07M | $390.31M |
Total Liabilities | $143.46M | $140.62M | $159.87M | $160.52M |
Cash & Equivalents | $120.86M | $166.73M | $51.70M | $81.31M |
Free Cash Flow OCF − CapEx | $-82.65M | $-151.81M | $-46.12M | $-93.19M |
Shares Outstanding | 386.38M | 377.53M | 80.23M | 79.48M |